PET/CT and choline: Diagnosis and staging

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 4, 2012, Pages 343-353

  Farsad, M ^a   Schwarzenbock S ^b   Krause, B J ^b  

^a Central Hospital   (Italy)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Choline PET; Diagnosis; Prostate cancer; Staging

Indexed keywords

CHOLINE C 11; FLUORINE 18;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; GLEASON SCORE; HUMAN; LYMPHADENOPATHY; MALE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION; TUMOR VOLUME;

CHOLINE; HUMANS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 84869840189     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007;57:90-104. (Pubitemid 46535709)
3. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-5. (Pubitemid 29265277)
4. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-8.
5. Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002;43:46-55. (Pubitemid 34101187)
6. Albrecht S, Buchegger F, Soloviev D, Zaidi H, Vees H, Khan HG et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007;34:185-96. (Pubitemid 46147501)
7. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005;32:344-50. (Pubitemid 40562127)
8. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-9.
9. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004:45:366-73.
10. Toth G, Lengyel Z, Balkay L, Salah MA, Tron L, Toth C. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 2005;173:66-9; discussion 9.
11. Watanabe H, Kanematsu M, Kondo H, Kako N, Yamamoto N, Yamada T, et al. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging. J Magn Reson Imaging 2010;31:1151-6.
12. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2011 Mar 7 [Epub ahead of print].
13. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003;90:525-33. (Pubitemid 37243700)
14. Casciani E, Gualdi GF. Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging 2006;31:490-9. (Pubitemid 46352054)
15. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002;21:937-46. (Pubitemid 34146307)
16. Ratnam S, Kent C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995;323:313-22.
17. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-603. (Pubitemid 32694969)
18. Hara T, Bansal A, DeGrado TR. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 2006;5:498-509. (Pubitemid 46142823)
19. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996 May-Jun;16(3B):1375-80.
20. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005;173:252-5. (Pubitemid 39627729)
21. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249-54. (Pubitemid 47544875)
22. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005;32:742-8. (Pubitemid 41125415)
23. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-9. (Pubitemid 46211588)
24. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065-73.
25. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E et al 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-60; discussion 60.
26. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45-53.
27. Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, et al. The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration. Clin Cancer Res 2011;17:3751-9.
28. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F et al 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254:925-33.
29. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18-23.
30. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8; discussion 8-9.
31. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253-63.
32. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47:262-9. (Pubitemid 46780891)
33. Li X, Liu Q, Wang M, Jin X, Yao S, Liu S et al. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin Nucl Med 2008;33:671-6.
34. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A et al 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54:392-401.
35. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-8. (Pubitemid 40571106)
36. Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. Eur J Cancer 2010;46:449-55.
37. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317-24. (Pubitemid 38314074)
38. Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 2005;74:214-20. (Pubitemid 41201531)
39. Souvatzoglou M, Gaertner FC, Schwarzenböck S, Beer AJ, Schwaiger M, Krause BJ. PET/CT for the diagnosis, staging and restaging of prostate cancer. Imaging Med 2011;3 [In press].
40. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4. (Pubitemid 23175983)
41. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
42. Rinnab L, Blumstein NM, Mottaghy FM, Hautmann RE, Kufer R, Hohl K et al 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007;99:1421-6. (Pubitemid 47164799)
43. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387-95.
44. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261:46-66.
45. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-5. (Pubitemid 39586006)
46. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006;176:2014-8; discussion 8-9.
47. Eschmann SM, Pfannenberg AC, Rieger A, Aschoff P, Muller M, Paulsen F, et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007;46:161-8; quiz N47-8.
48. Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G et al. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008;35:689-95.
49. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 2011;13:352-61.
50. Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011;60:125-30.
51. Contractor K, Challapalli A, Barwick T, Winkler M, Hellawell G, Hazell S, et al. Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 2011;17:7673-83.
52. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006;36:73-92. (Pubitemid 41782168)
53. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008;35:1766-74.
54. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009;11:446-54.
55. Gutman F, Aflalo-Hazan V, Kerrou K, Montravers F, Grahek D, Talbot JN. 18F-choline PET/CT for initial staging of advanced prostate cancer. AJR Am 7J Roentgenol 2006;187:W618-21.